ReviewImmuno-oncology technology2020
Nanobodies as non-invasive imaging tools.
Review in Immuno-oncology technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Bibliometric analysis of programmed death ligand-1 positron emission tomography probe research: development, landscape, and technological evolution.Nuclear medicine communications · 2026Article
- A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Development and Evaluation of "a PEGylated Anti-Tau ScFv for SPECT Imaging" in a Rat Model of Traumatic Brain Injury.Pharmaceutics · 2026Article
- Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.EJNMMI research · 2026Review
- Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches.Antibodies (Basel, Switzerland) · 2025Review
- AntigenApp: a laboratory data management system for nanobody generation and sequence analysis.Bioinformatics (Oxford, England) · 2025Article
- Synthesis and In Vitro Evaluation of a Scandium-44 Radiolabeled Nanobody as a PD-L1 PET Imaging Probe.Pharmaceutics · 2025Article
- Novel strategies for targeting tau oligomers in neurodegenerative diseases.Journal of neurology · 2025Review
- A Highly Sensitive Immunoassay to Enable Quantification of a Nanobody-Based Imaging Agent in Human Serum.The AAPS journal · 2025Article
- Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting.Nanomaterials (Basel, Switzerland) · 2025Review
- Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models.Scientific reports · 2024Article
- Preclinical development of novel PD-L1 tracers and first-in-human study of [Journal for immunotherapy of cancer · 2024Article
- A single-domain antibody for the detection of pathological Tau protein in the early stages of oligomerization.Journal of translational medicine · 2024Article
- Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy.Cell death & disease · 2024Review
- Making the effect visible - OX40 targeting nanobodies forFrontiers in immunology · 2024Article
- The role of CD8 PET imaging in guiding cancer immunotherapy.Frontiers in immunology · 2024Review
- Ultrasensitive Electrochemical Immunosensors Using Nanobodies as Biocompatible Sniffer Tools of Agricultural Contaminants and Human Disease Biomarkers.Micromachines · 2023Review
- Reviving a Classic Antigen with a Cutting-Edge Approach: Nanobodies for HER2+ Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Site-specificEJNMMI radiopharmacy and chemistry · 2023Article
- Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Antibodies and antibody fragments have found wide application for therapeutic and diagnostic purposes. Single-domain antibody fragments, also known as 'heavy-chain variable domains' or 'nanobodies', are a recent addition to the toolbox. Discovered some 30 years ago, nanobodies are the smallest antibody-derived fragments that retain antigen-binding properties. Their small size, stability, specificity, affinity and ease of manufacture make them appealing for use as imaging agents in the laboratory and the clinic. With the recent surge in immunotherapeutics and the success of cancer immunotherapy, it is important to be able to image immune responses and cancer biomarkers non-invasively to allocate resources and guide the best possible treatment of patients with cancer. This article reviews recent advances in the application of nanobodies as cancer imaging agents. While much work has been done in preclinical models, first-in-human applications are beginning to show the value of nanobodies as imaging agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.